Loading
If every lab had access to the same set of well-characterised tumour models, results could be compared directly instead of each lab using its own private models.
Organoid and patient-derived xenograft results are hard to compare because models differ between labs. A curated reference panel (for example 50 organoids and 50 PDX models per major cancer, fully characterised, distributed at cost by a repository such as the Human Cancer Models Initiative or EurOPDX) with standard culture protocols and published baseline drug responses would serve as the common ground for method comparison and replication.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Preclinical results do not reproduce, Patient-derived organoids.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Cancer Models (PDCM Finder) & HCMI, Preclinical results do not reproduce, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, Preclinical results do not reproduce, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, Preclinical results do not reproduce, Patient-derived organoids.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Every drug screen includes standard reference compounds whose performance is published, Preclinical results do not reproduce, Lab models that fail to predict what happens in patients.